ArticleCardio-oncology (London, England)2025
Mortality differences in coronary patients with breast cancer treated with trimetazidine dihydrochloride: potential therapeutic implications.
Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTrimetazidine, an anti-angina drug with metabolic regulatory effects, has been observationally associated with reduced malignancy risk. However, whether it has clinical implications for established breast cancer is unknown.
methodsWe retrospectively studied 2,526 patients with pre-existing or de novo breast cancer and ischemic heart disease (IHD) who received trimetazidine therapy or oral nitrate, identified from the Hong Kong Clinical Data Analysis and Reporting System (CDARS) between January 1, 1999, and December 31, 2020. Subjects were classified as trimetazidine users (n=169) versus non-users (n=2,357). Multivariable Cox regression was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of all-cause mortality in the pre-existing breast cancer group.
resultsAfter a mean follow-up duration of 4,235± 2,272 days, patients with pre-existing breast cancer who received trimetazidine experienced had a longer overall survival from all-cause mortality than the control group (Mean survival, days [95%CI]; Control, 4,543 [4,163-4,923]; Trimetazidine, 5,405 [2,857-7,953]; Breslow [Generalised Wilcoxon], 5.07, p=.02). Cox regression showed that use of trimetazidine was independently associated with lower all-cause mortality (adjusted HR, 0.48; 95% CI, 0.48-0.98; P = .04). Sensitivity analyses analyzing subjects with pre-existing or de novo breast cancer yielded similar findings (adjusted HR, 0.75; 95% CI, 0.60-0.94; P = .01). The survival benefits were mainly conferred to non-cardiovascular mortality (Breslow [Generalised Wilcoxon], 10.6, p=.001).
conclusionsTrimetazidine use is associated with a lower risk of all-cause mortality among breast cancer patients with IHD. While causality cannot be established at present, further randomized controlled trials are warranted to confirm our findings and further elucidate the underlying mechanisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.